The purpose of this research is to compare patients with aneurysmal subarachnoid hemorrhage on dexmedetomidine compared to propofol to assess if one group has decreased inflammation. The investigators hypothesis is that the group assigned to receive dexmedetomidine will have a more profound decrease in markers of inflammation over time.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
4
0.2-1.5 mcg/kg/hr
5-80 mcg/kg/min
University Hospital
Cincinnati, Ohio, United States
Changes between serum and CSF cytokines over 48 hours
Measure the baseline level (at enrollment) of inflammatory markers tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), glial fibrially acidic protein (GFAP), and malondialdehyde (MDA) as measured in both serum and cerebrospinal fluid (CSF) in 10 patients with aneurysmal subarachnoid hemorrhage (aSAH).
Time frame: 0, 24 and 48 hours
Sedative and analgesic medication requirements
Sedation requirements between the two groups will be assessed by comparing total daily dose and average daily fentanyl doses in the 24 hours following surgery. The total number of patients requiring propofol rescue in the dexmedetomidine group and the total daily dose and average daily dose of the propofol used in the dexmedetomidine group will be recorded.
Time frame: 2 weeks
Sedation scores (RASS and CAM-ICU)
Time frame: 2 weeks
ICU length of stay
Time frame: 2 weeks
Hospital length of stay
Time frame: 2 weeks
Glasgow Outcome Scores Extended (GOSE) at discharge
Time frame: 2 weeks
Incidence of delayed cerebral ischemia (DCI)
Time frame: 2 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.